Abstract:OBJECTIVE: Cutaneous scar formation is a significant clinical concern with substantial functional and psychosocial sequelae that translates to an annual cost of $3 billion in the U.S alone. In particular, trauma and burn often lead to severe hypertrophic scarring with disfigurement and dysfunction. The persistence and accumulation of myofibroblasts after reepithelization have been considered to play a critical role in excessive extracellular matrix (ECM) deposition and scar contraction that comprise hypertrophic scarring. Our previous studies indicated that fibromodulin (FMOD) plays an essential role in fetal and adult wound healing. For instance, FMOD promotes dermal fibroblast migration and myofibroblast conversion and contraction that lead to fast wound closure and reduced wound size. This study aimed to further explore the role of FMOD in cutaneous wound healing at the regeneration stage, especially rapid clearance of myofibroblast from the wound site after wound closure, and evaluate the clinical potential of FMOD-based therapeutics. METHOD: Full-thickness skin ellipses with the underlying panniculuscarnosus muscle were excised to generate primary closure wounds in not only mouse and rat models but also pig models with high-mechanical loading. Wounds were treated once with FMOD or PBS control at the time of injury. Myofibroblast accumulation was evaluated by immunohistochemical staining against α-smooth muscle actin (α-SMA). RNA was isolated from the wounds and subjected to real-time PCR to determineinterleukin (IL)1β expression. Meanwhile, primary rat dermal fibroblasts (RDFs) and a human hTERT immortalized dermal fibroblast cell line, BJ-5ta, were converted into myofibroblasts by transforming growth factor (TGF)β1 stimulation. The apoptosis of yield myofibroblasts with or without FMOD was measured by terminaldeoxynucleotidyltransferasedUTP nick end labeling (TUNEL). Gene expression was assessed by real-time PCR. RESULTS:In vivo, Fmod-/- mouse wounds representing a lost-of-function model presented markedly increased myofibroblasts after wound closure compared with wild-type (WT) controls. Intradermal injection of FMOD representing gain-of-function models led to significantly decreased myofibroblast accumulation in the wound areas of multiple animal species, including WT mice and Fmod-/- mice, rats and pigs with high-mechanical loading wounds. Moreover, FMOD injection significantly stimulated Il1β expression, which likely contributed to the diminished number of myofibroblasts. In vitro, FMOD alone stimulated myofibroblast (but not fibroblast) apoptosis as effectively as IL1β. Remarkably, even in the presence of TGFβ1 that completely blocked the effect of IL1β, FMOD promoted myofibroblast apoptosis. Meanwhile, IL1 receptor antagonist (IL1RA) fully rescued myofibroblasts from FMOD-induced apoptosis and blocked FMOD-stimulated myofibroblast IL1β expression. Thus, FMOD selectively promoted apoptosis of myofibroblasts but not fibroblasts via an IL1β-dependent pathway. CONCLUSION: FMOD accelerates myofibroblast clearance during cutaneous wound healing that significantly reduces scarring, especially hypertrophic scarring, through an IL1β-dependent pathway. Since among mammalian skin porcine skin most closely approximates human skin in anatomic structure, mechanical properties and wound healing and pig models are required by the U.S. Food and Drug Administration (FDA) for human skin product testing, our current study presents a remarkable translational potential of FMOD for human scar management.

Targeted Killing of Myofibroblasts by Biosurfactant Di-Rhamnolipid Suggests a Therapy Against Scar Formation.

Co-transfection of Hepatocyte Growth Factor and Truncated TGF-β Type II Receptor Inhibit Scar Formation

The Effect of Topical Ramipril and Losartan Cream in Inhibiting Scar Formation

Liposome‐encapsulated statins reduce hypertrophic scarring through topical application

The Mechanism of Lactobacillus Delbruckii Inhibiting Hypertrophic Scar Fibrosis Based on Proteome and Transcriptome Analysis

Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis

Abstract 12: Fibromodulin Selectively Promotes Myofibroblast Apoptosis During Cutaneous Wound Healing

A Strategy Involving Microporous Microneedles Integrated with CAR‐TREM2‐Macrophages for Scar Management by Regulating Fibrotic Microenvironment

Simultaneous Silencing of TGF-β1 and COX-2 Reduces Human Skin Hypertrophic Scar Through Activation of Fibroblast Apoptosis

The Anti-Scar Effects of Basic Fibroblast Growth Factor on the Wound Repair in Vitro and in Vivo

Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring

Targeted Apoptosis of Myofibroblasts by Elesclomol Inhibits Hypertrophic Scar Formation.

Expression, Purification, and Characterization of Scar Tissue Neovasculature Endothelial Cell-Targeted Rhil10 in Escherichia Coli

Treatment with Lactobacillus Delbruckii Inhibits Hypertrophic Scar Fibrosis

Fibromodulin reduces scar size and increases scar tensile strength in normal and excessive-mechanical-loading porcine cutaneous wounds.

Regulating Inflammation Using Acid-Responsive Electrospun Fibrous Scaffolds for Skin Scarless Healing.

Rynchopeterine inhibits the formation of hypertrophic scars by regulating the miR-21/HIF1AN axis

A New Strategy to Inhibit Scar Formation by Accelerating Normal Healing Using Silicate Bioactive Materials

3D-Printed Dermis-Specific Extracellular Matrix Mitigates Scar Contraction Via Inducing Early Angiogenesis and Macrophage M2 Polarization

3D-Printed Biomimetic Scaffold with Liposome-Encapsulated SB431542 Promotes Scarless Wound Healing

Xiamenmycin Attenuates Hypertrophic Scars by Suppressing Local Inflammation and the Effects of Mechanical Stress